BioCentury | Apr 12, 2021
Product Development

COVID Quick Takes: subcutaneous Regeneron mAbs prevent symptomatic COVID; plus Pfizer-BionTech, J&J, Akili and Kiniksa

...By Sandi Wong, Assistant Editor Regeneron reported Phase...
...to more severe disease. In the trial, which Regeneron Pharmaceuticals Inc....
...BNT162, BNT162b2) COVID-19 Vaccine Janssen (Ad26.COV2.S, JNJ-78436735) mavrilimumab (cam-3001) AKL-T01, SDT-001 Regeneron Pharmaceuticals Inc. Pfizer...
BioCentury | Apr 6, 2021
Regulation

April 5 Quick Takes: FDA extends review of Rinvoq in atopic dermatitis; plus Acadia, Supernus

...indication versus three other Phase III programs as well as marketed drug Dupixent dupilumab from Regeneron Pharmaceuticals Inc....
BioCentury | Apr 1, 2021
Product Development

April 1 Quick Takes: BioNTech, Pfizer to seek full approval of vaccine; plus CEPI’s call and FDA’s latest batch of expanded labels

...Corp. (NASDAQ:UTHR) and Sanofi (Euronext:SAN; NASDAQ:SNY) and expanded the labels of PCSK9 inhibitor Praluent alirocumab from Regeneron Pharmaceuticals Inc....
...Compound #), REGN727 (Compound #), alirocumab (Generic), Praluent (Other) Coalition for Epidemic Preparedness Innovations (CEPI) BioNTech SE Pfizer Inc. Regeneron Pharmaceuticals Inc. United...
BioCentury | Apr 1, 2021
Product Development

Lilly-Vir mAb cocktail could expand treatment to low-risk COVID-19 patients

...which Lilly developed with Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180); and the two-mAb cocktail REGEN-COV-2 from Regeneron Pharmaceuticals Inc....
BioCentury | Mar 27, 2021
Product Development

A Vir’s-eye view of the path forward for its COVID mAbs

...the biotech’s COVID mAb pipeline than they have on Lilly’s products. An authorized mAb cocktail from Regeneron Pharmaceuticals Inc....
...compete with vaccines. Lilly and Regeneron are both testing subcutaneous versions of their drugs. In January, Regeneron...
...COMET-TAIL, in high-risk patients; and COMET-STAR, in uninfected individuals as prophylaxis. In addition to Lilly and Regeneron’s...
BioCentury | Mar 26, 2021
Product Development

March 25 COVID Quick Takes: Biofire gets FDA’s first premarket authorization for COVID-19 test; plus CureVac, CanSino, Regeneron and AZ

...China, Mexico and Pakistan.Phase III readout for Regeneron...
...Ad5-nCoV) casirivimab/imdevimab (REGEN-COV, REGN-COV2, REGN-COVID19, REGN10933/REGN10987) CureVac N.V. CanSino Biologics Inc. Regeneron Pharmaceuticals Inc. AstraZeneca...
BioCentury | Mar 26, 2021
Product Development

As U.S. pulls Lilly's monotherapy, Regeneron combo appears most effective against COVID variants

...Lilly and the REGEN-COV (casirivimab/imdevimab) cocktail from Regeneron Pharmaceuticals Inc....
...and authorized mAb cocktails from Lilly and Regeneron...
...first identified in South Africa. Products from Regeneron...
BioCentury | Mar 20, 2021
Product Development

March 19 Quick Takes: Ovarian readout for Rubraca lifts Clovis shares; plus Keytruda-Lenvima combo meets in endometrial, approvals for Kiniksa, J&J and more

...Former compound #), AG-014699 (Former compound #), rucaparib (Generic) Keytruda, pembrolizumab (MK-3475, lambrolizumab) mavacamten (SAR439152, myk-461) Arcalyst, Rilonacept Regeneron...
BioCentury | Mar 17, 2021
Product Development

U.S. limits distribution of Lilly-AbCellera COVID-19 mAb over concerns it is ineffective against variant

...U.S.: the bamlanivimab/etesevimab combination from Eli Lilly and Co. (NYSE:LLY) and the casirivimab/imdevimab cocktail from Regeneron Pharmaceuticals Inc....
...mAbs from Lilly and its partners would be most likely to lose efficacy, while products from Regeneron...
...to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021. Steve Usdin Eli Lilly and Co. Regeneron Pharmaceuticals Inc. covid-19 cov19count ASPR cov19count...
BioCentury | Mar 17, 2021
Product Development

March 17 Quick Takes: FDA extends review of Rinvoq in psoriatic arthritis; plus Merck, PharmaEssentia, Lilly, Roche and more

...in efficacy in the indication versus three other Phase III programs and Dupixent dupilumab from Regeneron Pharmaceuticals Inc....
Items per page:
1 - 10 of 1844
BioCentury | Apr 12, 2021
Product Development

COVID Quick Takes: subcutaneous Regeneron mAbs prevent symptomatic COVID; plus Pfizer-BionTech, J&J, Akili and Kiniksa

...By Sandi Wong, Assistant Editor Regeneron reported Phase...
...to more severe disease. In the trial, which Regeneron Pharmaceuticals Inc....
...BNT162, BNT162b2) COVID-19 Vaccine Janssen (Ad26.COV2.S, JNJ-78436735) mavrilimumab (cam-3001) AKL-T01, SDT-001 Regeneron Pharmaceuticals Inc. Pfizer...
BioCentury | Apr 6, 2021
Regulation

April 5 Quick Takes: FDA extends review of Rinvoq in atopic dermatitis; plus Acadia, Supernus

...indication versus three other Phase III programs as well as marketed drug Dupixent dupilumab from Regeneron Pharmaceuticals Inc....
BioCentury | Apr 1, 2021
Product Development

April 1 Quick Takes: BioNTech, Pfizer to seek full approval of vaccine; plus CEPI’s call and FDA’s latest batch of expanded labels

...Corp. (NASDAQ:UTHR) and Sanofi (Euronext:SAN; NASDAQ:SNY) and expanded the labels of PCSK9 inhibitor Praluent alirocumab from Regeneron Pharmaceuticals Inc....
...Compound #), REGN727 (Compound #), alirocumab (Generic), Praluent (Other) Coalition for Epidemic Preparedness Innovations (CEPI) BioNTech SE Pfizer Inc. Regeneron Pharmaceuticals Inc. United...
BioCentury | Apr 1, 2021
Product Development

Lilly-Vir mAb cocktail could expand treatment to low-risk COVID-19 patients

...which Lilly developed with Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180); and the two-mAb cocktail REGEN-COV-2 from Regeneron Pharmaceuticals Inc....
BioCentury | Mar 27, 2021
Product Development

A Vir’s-eye view of the path forward for its COVID mAbs

...the biotech’s COVID mAb pipeline than they have on Lilly’s products. An authorized mAb cocktail from Regeneron Pharmaceuticals Inc....
...compete with vaccines. Lilly and Regeneron are both testing subcutaneous versions of their drugs. In January, Regeneron...
...COMET-TAIL, in high-risk patients; and COMET-STAR, in uninfected individuals as prophylaxis. In addition to Lilly and Regeneron’s...
BioCentury | Mar 26, 2021
Product Development

March 25 COVID Quick Takes: Biofire gets FDA’s first premarket authorization for COVID-19 test; plus CureVac, CanSino, Regeneron and AZ

...China, Mexico and Pakistan.Phase III readout for Regeneron...
...Ad5-nCoV) casirivimab/imdevimab (REGEN-COV, REGN-COV2, REGN-COVID19, REGN10933/REGN10987) CureVac N.V. CanSino Biologics Inc. Regeneron Pharmaceuticals Inc. AstraZeneca...
BioCentury | Mar 26, 2021
Product Development

As U.S. pulls Lilly's monotherapy, Regeneron combo appears most effective against COVID variants

...Lilly and the REGEN-COV (casirivimab/imdevimab) cocktail from Regeneron Pharmaceuticals Inc....
...and authorized mAb cocktails from Lilly and Regeneron...
...first identified in South Africa. Products from Regeneron...
BioCentury | Mar 20, 2021
Product Development

March 19 Quick Takes: Ovarian readout for Rubraca lifts Clovis shares; plus Keytruda-Lenvima combo meets in endometrial, approvals for Kiniksa, J&J and more

...Former compound #), AG-014699 (Former compound #), rucaparib (Generic) Keytruda, pembrolizumab (MK-3475, lambrolizumab) mavacamten (SAR439152, myk-461) Arcalyst, Rilonacept Regeneron...
BioCentury | Mar 17, 2021
Product Development

U.S. limits distribution of Lilly-AbCellera COVID-19 mAb over concerns it is ineffective against variant

...U.S.: the bamlanivimab/etesevimab combination from Eli Lilly and Co. (NYSE:LLY) and the casirivimab/imdevimab cocktail from Regeneron Pharmaceuticals Inc....
...mAbs from Lilly and its partners would be most likely to lose efficacy, while products from Regeneron...
...to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021. Steve Usdin Eli Lilly and Co. Regeneron Pharmaceuticals Inc. covid-19 cov19count ASPR cov19count...
BioCentury | Mar 17, 2021
Product Development

March 17 Quick Takes: FDA extends review of Rinvoq in psoriatic arthritis; plus Merck, PharmaEssentia, Lilly, Roche and more

...in efficacy in the indication versus three other Phase III programs and Dupixent dupilumab from Regeneron Pharmaceuticals Inc....
Items per page:
1 - 10 of 1844